Search
Phio Pharmaceuticals Corp
PHIOAdd to Watchlist
1.000USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
11.62MMarket Cap
LossP/E TTM
More Details of Phio Pharmaceuticals Corp Company
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
Phio Pharmaceuticals Corp Info
Ticker SymbolPHIO
Company namePhio Pharmaceuticals Corp
IPO dateMay 10, 2012
CEOBitterman (Robert J)
Number of employees5
Security typeOrdinary Share
Fiscal year-endMay 10
Address411 Swedeland Road
CityKING OF PRUSSIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19406
Phone15087673861
Websitehttps://phiopharma.com/
Ticker SymbolPHIO
IPO dateMay 10, 2012
CEOBitterman (Robert J)
Company Executives of Phio Pharmaceuticals Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Robert J. Bitterman
Mr. Robert J. Bitterman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
51.42K
+19.45%
Mr. David H. Deming
Mr. David H. Deming
Independent Director
Independent Director
37.80K
+62.96%
Dr. Curtis A. Lockshin, Ph.D.
Dr. Curtis A. Lockshin, Ph.D.
Independent Director
Independent Director
2.35K
-1307.90%
Dr. Jonathan E. Freeman, Ph.D.
Dr. Jonathan E. Freeman, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia A. (Pat) Bradford
Ms. Patricia A. (Pat) Bradford
Independent Director
Independent Director
--
--
Ms. Lisa Carson
Ms. Lisa Carson
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert J. Bitterman
Mr. Robert J. Bitterman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
51.42K
+19.45%
Mr. David H. Deming
Mr. David H. Deming
Independent Director
Independent Director
37.80K
+62.96%
Dr. Curtis A. Lockshin, Ph.D.
Dr. Curtis A. Lockshin, Ph.D.
Independent Director
Independent Director
2.35K
-1307.90%
Dr. Jonathan E. Freeman, Ph.D.
Dr. Jonathan E. Freeman, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia A. (Pat) Bradford
Ms. Patricia A. (Pat) Bradford
Independent Director
Independent Director
--
--
Ms. Lisa Carson
Ms. Lisa Carson
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance and Administration
--
--
FAQs
Who are the top five shareholders of Phio Pharmaceuticals Corp?
The top five shareholders of Phio Pharmaceuticals Corp are: Mr. Robert J. Bitterman
How many institutions hold shares of Phio Pharmaceuticals Corp (PHIO)?
As of 2026Q1, 41 institutions hold shares of Phio Pharmaceuticals Corp, with a combined market value of approximately 1.10M, accounting for 9.48% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 6982.00.